Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Dare Bioscience Inc (NQ: DARE )

0.9901 USD +0.0001 (+0.01%)
Official Closing Price Updated: 5:55 PM EDT, Oct 27, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 196,229
Open 1.010
Bid (Size) 0.9901 (7)
Ask (Size) 1.000 (10)
Prev. Close 0.9900
Today's Range 0.9900 - 1.010
52wk Range 0.6902 - 2.220
Shares Outstanding 11,422,161
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Daré Bioscience to Present at the 2020 BIO Investor Forum Digital
From GlobeNewswire News Releases
Daré Bioscience Receives $0.9 million Under the Current Grant Supplement Award for Continued Development of its User-Controlled, Long Acting Reversible Contraceptive (DARE-LARC1)
Contraceptive Program Supported by approximately $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation to Date 
From GlobeNewswire News Releases

Performance

YTD
+17.17%
+17.17%
1 Month
-0.99%
-0.99%
3 Month
-17.49%
-17.49%
6 Month
-8.32%
-8.32%
1 Year
+15.13%
+15.13%

More News

Read More
Daré Bioscience Announces Participation in Two Upcoming Virtual Conferences
From GlobeNewswire News Releases
Daré Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs
From GlobeNewswire News Releases
Daré Bioscience Announces Publication of DARE-BV1 Proof of Concept Study for the Treatment of Bacterial Vaginosis
From GlobeNewswire News Releases
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-FRT1
From GlobeNewswire News Releases
Daré Bioscience Reports Second Quarter 2020 Financial Results and Provides Company Update
From GlobeNewswire News Releases
Daré Bioscience CEO to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference
From GlobeNewswire News Releases
Daré Bioscience to Host Second Quarter 2020 Financial Results and Company Update Conference Call and Webcast on August 12, 2020
From GlobeNewswire News Releases
Daré Bioscience Announces Initiation of Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-oral, Bio-identical Hormone Therapy for the Treatment of Menopausal Sympt
From GlobeNewswire News Releases
Daré Bioscience Announces Publication of a Peer-Reviewed Journal Article Supporting the Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.